Bibliografia
Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocr Rev 40(1):17–65
Ruggeri RM, Campennì A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, Cannavò S (2018) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest (E Pub ahead of print)
Morganstein DL, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J (2017) Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf) 86:614–620
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Gli Autori dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Rights and permissions
About this article
Cite this article
Peri, A., Presotto, E.M. Tireopatie in corso di terapia con inibitori dei check-point immunitari. L'Endocrinologo 20 (Suppl 1), 52–53 (2019). https://doi.org/10.1007/s40619-019-00555-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-019-00555-8